MAPS Launches a Practitioner Alliance. Who Actually Gets to Credential a Psilocybin Guide?

The short answer

On October 5, 2026, MAPS announced a partnership with the International Alliance of Psychedelic Therapy Practitioners to "strengthen professional education, support the development of clinical and ethical standards, and build the infrastructure needed for that growth."

Read it twice. It names no curriculum, no required hours, no cost, no certification criteria, and no assessment standard. The Alliance "will begin accepting new members this month." https://maps.org/2026/10/05/maps-partners-with-international-alliance-of-psychedelic-therapy-practitioners/

What it does name is people: Betty Aldworth, MAPS Co-Executive Director; Sara Gael, the Alliance's Interim Executive Director; and founding members including Annie and Michael Mithoefer, Marcela Ot'alora G, Bruce Poulter, Keren Tzarfaty, Ido Siemion and Ingrid Pacey. That is, substantially, the group that built the MDMA-assisted therapy model.

The timing is the actual news. Five weeks earlier, FDA held its first public hearing on how psychedelic therapy would be delivered if a drug is ever approved — and the written-comment window for that docket closed on October 5, the same day the announcement went out.

So the question on the table is simple and unanswered: when someone tells you they are a qualified psychedelic practitioner, who said so?

What the announcement contains, and what we could not find

We went looking for the Alliance as an institution. We did not find one. No own website, no published membership requirements, no dues schedule, no governance documents surfaced. Every description of it we could locate traces back to the October 5 MAPS release or to blogs repeating it. The release itself says the Alliance was "formed in 2023" while describing it as newly formed.

That is not an accusation. It is a statement of what is and is not verifiable right now, and it matters because the thing being launched is a credibility signal.

The release also grounds the therapeutic approach in "the Phase 2 and Phase 3 clinical trials conducted by Resilient Pharmaceuticals (formerly known as MAPS PBC and Lykos Therapeutics)." It reports no efficacy or safety data of its own, and — to its credit — does not claim any psychedelic therapy is approved.

For context on what MAPS already offers, its training page describes the International Psychedelic Therapy Education Program, launched in 2023: six-day intensives, with eligibility limited to providers "authorized to conduct therapy in their country" or researchers on an MDMA trial. No cost and no credential or certification is stated on that page either. https://maps.org/training

So the honest summary: a membership organisation has announced that standards are coming. Standards have not arrived.

FDA is already asking this exact question, in public, on the record

This is the primary document that makes the MAPS announcement interesting rather than routine.

FDA convened "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs" on September 14, 2026, hybrid, at White Oak, in collaboration with federal partners. https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026

The Federal Register notice (published July 14, 2026; Docket FDA-2026-N-7542) lists what FDA wanted input on. Among the topics, verbatim:

• "The evidence base for training and educational curricula"

• "Personnel and training needs by phase of care," including "minimum staffing during administration and monitoring"

• "the roles and qualifications of non-prescriber personnel"

• "Credentialing and licensure considerations, ranging from background education and experiential qualifications"

• "Mechanisms to prevent, detect, and report ethical violations by practitioners to appropriate authorities"

https://www.govinfo.gov/content/pkg/FR-2026-07-14/html/2026-14155.htm

FDA was explicit about what it was not asking about: scheduling, legalization, religious or personal use, or complaints about specific practitioners.

Separately, FDA finalized its guidance *Psychedelic Drugs: Considerations for Clinical Investigations* in July 2026 (Docket FDA-2023-D-1987, finalizing the June 2023 draft). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations

One caveat we will not paper over: the guidance PDF was not machine-readable for us this session. The widely circulated specifics — two trained monitors per dosing session, a lead monitor with graduate-level training and independent licensure, an assistant with nursing or bachelor's-level qualifications plus a year of clinical experience, a licensed physician reachable on site within 15 minutes — come to us from Baker Donelson's named summary of that guidance, not from FDA text we read ourselves. https://www.bakerdonelson.com/fda-finalizes-guidance-on-psychedelic-drugs-for-clinical-investigations-key-implications-for-hospitals-and-trial-sponsors

Attribute accordingly. The direction of travel is clear either way: the federal model being sketched is clinical, licensed, and medically backstopped.

Oregon has the only real-world data — and it points straight at facilitator training

Oregon and Colorado are the only US settings where anyone legally delivers psilocybin services, and both use a non-clinical facilitator model. Oregon is also the only place generating peer-reviewed outcome data.

The cohort study (human, prospective, uncontrolled — not an RCT). Korthuis, Cook, Gregoire and colleagues, *JAMA Network Open* 2026;9(8):e2630608, published August 19, 2026. Single-arm, 346 adults at 24 of 26 active licensed service centers, enrolled November 2024 to March 2026, mean dose 31.9 mg. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2853028

Safety findings, which are the point here:

• 4 of 346 (1.2%) serious adverse reactions requiring medical attention — all in psychedelic-naive participants seeking help for mental health symptoms

• Facilitators reported only 1 of those 4. The authors note that day-of-session reporting mandates may underestimate harm

• Past-30-day HPPD symptoms in 10.0% at one month and 8.7% at three months (one participant with significant distress)

• New thoughts of dying or suicide rose from 1.0% at one week to 1.9% at three months

The study also reports large symptom improvements at three months — moderate-to-severe depression 42.2% to 16.5%, anxiety 45.1% to 13.2%, PTSD 48.0% to 16.8%. These are not treatment effects. The authors say plainly that the uncontrolled design precludes causal inference, the sample is roughly 5% of Oregon recipients, baseline symptoms were relatively low, and psychiatric diagnoses were unknown.

The training detail that matters: 83 licensed facilitators supervised those sessions, and the authors state Oregon requires state didactic training and a practicum but not professional clinical training — with medical screening and clinical support "typically outside facilitators' scope of practice."

What the rules actually require. LoParco, Bone, Galvin, Rossheim and Berg, *Health Behavior Research* 2026;9(1):20, reviewed them: 120 hours of instruction in 2024 rising to 128 after 2025, plus a 40-hour in-person practicum. The state exam is free, passes at 75%, and allows unlimited retakes. OHA-approved training programs fell from 24 in October 2024 to 16 in March 2026; 2026 tuition ran $3,000 to $14,175; course length ran 8 weeks to 12 months. Facilitator permits went from 356 in September 2024 to 345 in March 2026. Renewal requires at least four hours of continuing education. The authors flag the obvious: no state oversight of training program quality or cost, plus unlimited retakes, makes competence hard to verify. https://pmc.ncbi.nlm.nih.gov/articles/PMC13348737/

Program scale. Yu, Tafur, Moreno and Dahmer, *Frontiers in Psychiatry*, May 13, 2026, analysed Oregon's public dashboard for calendar 2025: 5,935 clients across 5,375 administration sessions, 7 severe reactions requiring hospital transport, and 32.6% of clients coming from outside Oregon. The authors state the program lacks validated outcome measures and that their study does not measure effectiveness. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2026.1777387/full

Oregon publishes its own numbers at https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-Data-Dashboard.aspx

The record the training model rests on includes the parts that failed review

If a group's authority comes from having run the trials, the trials are fair game.

The CRL. FDA declined approval of midomafetamine (NDA 215455) on August 9, 2024 and asked for an additional Phase 3 trial. FDA publicly released the letter on September 4, 2025. Per HCPLive's reading of the released document, FDA cited no durability data beyond 18 weeks, design flaws in the MPLONG follow-up, roughly 40% of participants having prior MDMA use, failure to collect effects participants and therapists considered favorable, unreported adverse events at multiple sites, and inconsistent adverse-event definitions between the training manual and the protocol. FDA's asks included full AE reporting, a third-party data audit, an arm without psychotherapy to isolate the drug's contribution, and MDMA–SSRI interaction studies. https://www.hcplive.com/view/fda-releases-crl-detailing-safety-concerns-mdma-assisted-therapy-ptsd

That second-to-last item is a training document failing a regulator on exactly the thing training documents are for.

The retractions. Three *Psychopharmacology* papers were retracted on August 10, 2024 for "protocol violations amounting to unethical conduct at the MP4 study site." On the long-term follow-up notice, the editors state the authors knew of the violations at submission, did not inform the journal, did not remove the site's data, and did not fully declare a competing interest. Feduccia agreed with the retraction but disagreed with its wording; Michael C. Mithoefer, Lisa Jerome, Berra Yazar-Klosinski and Rick Doblin disagreed. https://pmc.ncbi.nlm.nih.gov/articles/PMC11513715/

Worth stating plainly: Michael Mithoefer is named in the October 5, 2026 release as an Alliance founding member and is a named dissenter from that retraction.

One of the three retracted papers was the one on how discontinuing reuptake inhibitors affected MDMA therapy response. https://pmc.ncbi.nlm.nih.gov/articles/PMC11513749/ Part of the evidence base behind the interaction advice in this training lineage was itself withdrawn.

The independent review. ICER concluded it could not assess the balance of benefits and harms, citing "functional unblinding in the clinical trials and additional concerns around trial design and conduct," and said it was "not able to assess the extent that bias influenced reporting of benefits." Lykos replied that ICER lacked meaningful input from patient, caregiver and provider groups. Reported by Phil Taylor, pharmaphorum, May 15, 2024. https://pharmaphorum.com/news/icer-raps-conduct-lykos-psychedelic-trial-ptsd

Where it stands. Lykos was renamed Resilient Pharmaceuticals and, per Psychedelic Alpha on August 12, 2026, reportedly resubmitted the PTSD application without running the new Phase 3 trial FDA asked for, instead referencing other groups' studies, a new Phase 1 in 32 healthy volunteers, and an audit of its Phase 3 data. That report rests on anonymous sources; Resilient has not publicly discussed it; FDA has not confirmed acceptance for review; no PDUFA date is public. Do not read "FDA is reviewing" into this. https://psychedelicalpha.com/news/two-years-after-rejection-resilient-quietly-refiles-mdma-for-ptsd-application/

MAPS responded on August 10, 2026, framing the resubmission as reported rather than verified, and said it "has no active role in Resilient's drug development program." Doblin: "We believed the data were valid," while acknowledging positive adverse events "had not been gathered at that time," and "Despite partial functional unblinding, the therapists provided high-quality care." Aldworth: "The drug evaluation and regulation system was not designed to evaluate drugs delivered as part of therapy." https://maps.org/2026/08/10/maps-responds-to-report-of-progress-for-mdma-assisted-therapy-for-ptsd-with-fda/

What is actually legal, and what the facilitator model may not screen for

United States. There is no FDA-approved psilocybin product. Oregon's regulated services and Colorado's licensed healing centers operate under state law; Colorado splits oversight between DORA, which licenses facilitators, and the Department of Revenue's Natural Medicine Division, which licenses businesses (https://nmd.colorado.gov/). Nothing a state licenses changes federal law. Start at /legal-status, /legal-status/oregon and /legal-status/colorado, and compare the two models at /vs/oregon-vs-colorado-psilocybin-therapy.

Australia remains the one jurisdiction where authorised psychiatrists may prescribe psilocybine (for treatment-resistant depression) and MDMA (for PTSD), following down-scheduling effective July 1, 2023. RANZCP's guidance for authorised prescribers was last updated in May 2026. https://www.ranzcp.org/clinical-guidelines-publications/clinical-guidelines-publications-library/guidance-for-authorised-prescribers-of-mdma-and-psilocybin

The clinical evidence, at its actual size. Compass Pathways reported on February 17, 2026 that COMP006 — Phase 3, randomized, double-blind, 581 dosed — hit its primary endpoint: the 25 mg arm improved 3.8 MADRS points more than 1 mg at Week 6 (95% CI −5.8 to −1.8; p<0.001), with 39% of the 25 mg arm reaching a 25% or greater MADRS reduction. COMP005 showed −3.6 MADRS versus placebo. Six treatment-emergent serious adverse events in six participants (2%); across both Phase 3 trials, serious suicidal ideation under 1%, and the one serious adverse event of suicidal behaviour occurred in the 1 mg arm. A 3.6-to-3.8 point difference is a real result and a small one, in treatment-resistant depression specifically — not in general wellness, which is what 30.6% of Oregon clients cite as their reason for a session.

The screening gap. Oregon's own authors say medical screening and clinical support are typically outside facilitators' scope. That matters most for interactions and contraindications, where the evidence tiers differ sharply:

• Lithium. Nayak, Gukasyan and colleagues, *Pharmacopsychiatry* 2021;54(5):240–245, analysed online experience reports from Erowid, Shroomery and Reddit — the lowest evidence tier, not a clinical case series. Of 62 lithium-plus-classic-psychedelic reports, 47% involved seizures and a further 18% bad trips, versus zero of 34 lamotrigine reports. Weak data, alarming direction. See /guides/psilocybin-and-lithium.

• SSRIs. Becker et al., *Clinical Pharmacology & Therapeutics* 2022;111(4):886–895, is a human RCT crossover in healthy volunteers: escitalopram pretreatment did not alter psilocin pharmacokinetics and reduced anxiety-type negative effects. The study was sponsored by MindMed, and the authors themselves call for longer pretreatment and clinical populations. It does not license "SSRIs are fine." /guides/psilocybin-and-ssris

• MAOIs and other medications. Check /guides/psilocybin-and-maois and /guides/psilocybin-drug-interactions before anything else.

The JAMA cohort does not report the medication status of the four people who had serious reactions. We do not know whether any of these interactions were involved.

PsyBear takeaways

1. The announcement is an intention, not an infrastructure. No curriculum, no hours, no cost, no credential, and no independent footprint we could verify for the Alliance. Treat any claim of "Alliance-affiliated" training as unverified until the organisation publishes its own membership criteria.

2. FDA is the body actually deciding, and it has not decided. Docket FDA-2026-N-7542 asked who should train and credential practitioners and how ethical violations should be detected and reported. A trade group launching while that docket closes is positioning, which is legitimate — and worth naming.

3. The sharpest fact in the file is a reporting failure. Four serious adverse reactions in 346 Oregon participants; facilitators reported one. That is the clearest existing argument that current training does not reliably catch harm, and it comes from the state program's own data, not from critics.

4. Do not read the Oregon improvement numbers as treatment effects. Single-arm, uncontrolled, roughly 5% program coverage, unknown diagnoses. The only Phase 3 psilocybin effects are −3.6 and −3.8 MADRS points in treatment-resistant depression.

5. The MDMA record cuts both ways. The people who built the model also produced a training manual whose adverse-event definitions FDA found inconsistent with the protocol, and three papers retracted over site conduct. Expertise is real; so is the paper trail.

6. Until a credential exists, you do the screening. Ask a prospective facilitator what clinical licensure they hold, who their medical backstop is and how fast they can reach them, what their adverse-event reporting process is, and what medications they will refuse a client over. If the answers are vague, that is your answer. Preparation and containment basics: /guides/safe-trip, /guides/trip-preparation and /guides/psilocybin-therapy. Dose questions belong at /dosage, with a clinician.

Key Takeaways

Three bodies are competing to define who is qualified to sit with you on psilocybin: FDA, which has approved no psychedelic product and spent September 2026 publicly asking who should train and credential practitioners; Oregon and Colorado, which license facilitators under a deliberately non-clinical model; and now a trade association founded by the people who built the MDMA therapy protocol. The MAPS–Alliance release contains no curriculum, hours, cost, or certification criteria, and we could find no independent web presence for the Alliance at all. The hardest number in the whole story comes from Oregon: in a 346-person prospective cohort published in JAMA Network Open in August 2026, four participants had serious adverse reactions requiring medical attention and facilitators reported one of them. That is a training-and-reporting problem, not a molecule problem — and it is the question all three bodies are actually fighting over.

FAQ

Does the MAPS–Alliance partnership create a psychedelic therapy credential?

No. The October 5, 2026 release states an intention to "strengthen professional education, support the development of clinical and ethical standards, and build the infrastructure needed for that growth." It names no curriculum, required hours, cost, certification criteria, or assessment standard. The Alliance said it would begin accepting members that month.

What did FDA ask about practitioner training in 2026?

FDA held a public hearing on September 14, 2026, and the Federal Register notice for Docket FDA-2026-N-7542 solicited input on "the evidence base for training and educational curricula," "personnel and training needs by phase of care," "the roles and qualifications of non-prescriber personnel," "credentialing and licensure considerations," and "mechanisms to prevent, detect, and report ethical violations by practitioners to appropriate authorities." Comments closed October 5, 2026.

Did Oregon facilitators report serious adverse reactions?

Not all of them. In Korthuis, Cook, Gregoire et al., JAMA Network Open 2026;9(8):e2630608, four of 346 participants (1.2%) had serious adverse reactions requiring medical attention, and facilitators reported one of the four. The authors note that day-of-session reporting mandates may underestimate harm.

What training does Oregon actually require of a psilocybin facilitator?

Per LoParco et al., Health Behavior Research 2026;9(1):20: 120 hours of instruction in 2024 rising to 128 after 2025, plus a 40-hour in-person practicum, and a free state exam with a 75% pass mark and unlimited retakes. Professional clinical training is not required, and the JAMA authors note that medical screening and clinical support are typically outside facilitators' scope of practice.

How large is the Phase 3 psilocybin effect for depression?

Small but statistically significant. Compass Pathways reported on February 17, 2026 that in COMP006 the 25 mg arm improved 3.8 MADRS points more than the 1 mg arm at Week 6 (95% CI −5.8 to −1.8; p<0.001), and COMP005 showed −3.6 MADRS versus placebo. Both are in treatment-resistant depression, and no FDA-approved psilocybin product exists.

Has the MDMA application been resubmitted to FDA?

Psychedelic Alpha reported on August 12, 2026 that Resilient Pharmaceuticals, formerly Lykos, resubmitted without running the new Phase 3 trial FDA requested. That report relies on anonymous sources, Resilient has not publicly discussed it, FDA has not confirmed acceptance for review, and no PDUFA date is public.

Related resources

• Psilocybin Therapy Guide
• Oregon vs Colorado Psilocybin Therapy
• Oregon Legal Status
• Psilocybin Drug Interactions
• Psilocybin and Lithium
• Safe Trip Guide